​

SAB Biotherapeutics Stock (NASDAQ:SABS)

ForecastOwnershipFinancialsChart
SAB Biotherapeutics by TradingView

Previous Close

$3.45

52W Range

$1.85 - $5.15

50D Avg

$3.66

200D Avg

$3.71

Market Cap

$33.26M

Avg Vol (3M)

$903.20K

Beta

0.53

Div Yield

-

SABS Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

86

IPO Date

Feb 09, 2021

Website

SABS Performance

SABS Financial Summary

Dec 25Dec 24Dec 23
Revenue-$1.32M$2.24M
Operating Income$-48.95M$-42.91M$-38.08M
Net Income$13.27M$-34.11M$-42.19M
EBITDA$-48.95M$-28.99M$-38.13M
Basic EPS$0.22$-3.68$-7.64
Diluted EPS$-0.79$-3.68$-7.64

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PLURPluri Inc.
NXTCNextCure, Inc.
QTTBQ32 Bio Inc.
EVAXEvaxion Biotech A/S
JSPRJasper Therapeutics, Inc.
VRCAVerrica Pharmaceuticals Inc.
BOLDBoundless Bio, Inc.
GBIOGeneration Bio Co.
ANTXAN2 Therapeutics, Inc.